AbbVie secures positive EU panel backing to expand Maviret to acute Hepatitis C
AbbVie (NYSE:ABBV) announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion recommending the approval of Maviret (glecaprevir/pibrentasvir) for the treatment of acute hepatitis C virus (HCV) infection.


_1405545_640x360_2501025859508-640x360.webp&w=3840&q=75)


_1405519_640x360_2501023299537-640x360.webp&w=3840&q=75)

_1405473_640x360_2501024323554-640x360.webp&w=3840&q=75)
_1405449_640x360_2501017155965-640x360.webp&w=3840&q=75)


